MIST compared with RCKT: revenue, margins and what each company keeps, and the suppliers and customers both name

MISTMilestone Pharmaceuticals Inc.

Mkt capRevenueRevenue

RCKTRocket Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

MISTMilestone Pharmaceuticals Inc.

RCKTRocket Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MIST1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±57.2%▼−11.42%×0.20

RCKT

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.1%▼−3.85%×0.13

May 8 '26±25.4%▼−1.09%×0.04

= impliedMIST realized, solidRCKT realized, hatchedOne scale, both sides: full bar = 58%× = |realized| ÷ impliedSource: market data

Q1 FY26

±17.9%

▲+10.60%

×0.59

Q3 FY25±24.5%▼−1.86%×0.08

MISTMilestone Pharmaceuticals Inc.

0.74▲+1.96%· post 0.74

Mkt cap$90.9MRevenue$559,000Q2 FY26

RCKTRocket Pharmaceuticals, Inc.

2.48▲+1.64%· post 2.48

ClosedNov 2 '26

Mkt cap$267.9MRevenue—

Compare

ClosedNov 2 '26

MISTMilestone Pharmaceuticals Inc.

RCKTRocket Pharmaceuticals, Inc.

0.74▲+1.96%post 0.74

Price

2.48▲+1.64%post 2.48

$90.9M

Mkt cap

$267.9M

Q2 FY26$559,000

Revenue

—

MIST0.74▲+1.96%vsRCKT2.48▲+1.64%ClosedNov 2 '26